Free Trial
NYSE:PRME

Prime Medicine 11/12/2024 Earnings Report

Prime Medicine logo
$1.22 -0.05 (-3.57%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.20 -0.02 (-1.23%)
As of 05/30/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Prime Medicine Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$55.00 million
Beat/Miss
Missed by -$54.79 million
YoY Revenue Growth
N/A

Prime Medicine Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Prime Medicine Earnings Headlines

Citigroup Downgrades Prime Medicine (PRME)
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
Prime Medicine (NYSE:PRME) Earns Neutral Rating from Citigroup
See More Prime Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email.

About Prime Medicine

Prime Medicine (NYSE:PRME), a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

View Prime Medicine Profile

More Earnings Resources from MarketBeat